Neuropsychiatric aspects of Parkinson's disease: Recent advances

Current Psychiatry Reports

Volumn 5, Issue 1, 2003, Pages 68-76

  Marsh, Laura ^a   Berk, Ariel ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMPHETAMINE; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; GABAPENTIN; HYPNOTIC SEDATIVE AGENT; LEVODOPA; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; QUETIAPINE; REBOXETINE; RISPERIDONE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

AGRANULOCYTOSIS; ANXIETY DISORDER; APATHY; BRAIN DEPTH STIMULATION; CELL TRANSPLANTATION; CLINICAL FEATURE; COGNITION; DEGENERATIVE DISEASE; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE ASSOCIATION; ELECTROCONVULSIVE THERAPY; EMBRYO CELL; HEADACHE; HUMAN; HYPERTENSION; MEDICAL DECISION MAKING; MEDICAL RESEARCH; MENTAL DISEASE; MOTOR DYSFUNCTION; MYOCARDITIS; NAUSEA; NEUROPSYCHIATRY; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSTATIC HYPOTENSION; PALLIDOTOMY; PARKINSON DISEASE; PSYCHOLOGICAL ASPECT; PSYCHOSIS; QUALITY OF LIFE; REVIEW; SEIZURE; SEROTONIN SYNDROME; THALAMOTOMY; THROMBOEMBOLISM; TREATMENT OUTCOME; AGED; MIDDLE AGED;

AGED; HUMANS; MIDDLE AGED; PARKINSON DISEASE;

EID: 0642345705     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-003-0012-6     Document Type: Review

References (138)

1. Cummings JL: Understanding Parkinson disease. JAMA 1999, 281:376-378.
2. Starkstein SE, Mayberg HS: Depression in Parkinson's disease. In Depression in Neurologic Disease. Edited by Starkstein SE, Robinson RG. Baltimore: Johns Hopkins University Press; 1993:97-116.
3. Gonera EG, van't Hof M, Berger JC, et al.: Symptoms and duration of the prodromal phase in Parkinson's disease. Mov Disord 1997, 12:871-876.
4. Shiba M, Bower JH, Maraganore DM, et al.: Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord 2000, 15:669-677.
5. Schuurman AG, van den Aker M, Ensinck KTJL, et al.: Increased risk of Parkinson's disease after depression: a retrospective cohort study. Neurology 2002, 58:1501-1504.
6. Santamaria J, Tolosa E, Valles A: Parkinson's disease with depression: a possible subgroup of idiopathic Parkinsonism. Neurology 1986, 36:1130-1133.
7. The Global Parkinson's Disease Survey (GPDS) Steering Committee: Factors impacting on quality of life in Parkinson's disease: results from an international survey. Mov Disord 2002, 17:60-67.
8. Kuopio A-M, Marttila RJ, Helenius H, et al.: The quality of life in Parkinson's disease. Mov Disord 2000, 15:216-223.
9. Schrag A, Jahanshahi M, Quinn N: What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 2000, 69:308-312.
10. Shulman LM, Taback RL, Bean J, Weiner WJ: Comorbidity of the nonmotor symptoms of Parkinson's disease. Mov Disord 2001, 16:507-510.
11. Houeto JL, Mesnage V, Mallet L, et al.: Behavioral disorders, Parkinson's disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry 2002, 72:701-707.
12. Green J, McDonald WM, Vitek JL, et al.: Neuropsychological and psychiatric sequelae of pallidotomy for PD: clinical trial findings. Neurology 2002, 58:858-865.
13. Goetz CG, Stebbins GT: Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993, 43:2227-2229.
14. Hoogendijk WJG, Sommer IEC, Tissingh G, et al.: Depression in Parkinson's disease: the impact of symptom overlap on prevalence. Psychosomatics 1998, 39:416-421.
15. Slaughter JR, Slaughter KA, Nichols D, et al.: Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2001, 13:187-196.
16. Starkstein SE, Mayberg HS, Leiguarda R, et al.: A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1992, 55:377-382.
17. Shulman LM, Leifert R, Singer C, Weiner WJ: The diagnostic accuracy of neurologists for anxiety, depression, fatigue, and sleep disorders in Parkinson's disease. Mov Disord 1997, 12(suppl):127
18. Happe S, Schrödl B, Faltl M, et al.: Sleep disorders and depression in patients with Parkinson's disease. Acta Neurol Scand 2001, 104:275-280.
19. Marsh L: Neuropsychiatric aspects of Parkinson's disease. Psychosomatics 2000, 41:15-23.
20. Schiffer RB, Kurlan R, Rubin A, Boer S: Evidence for atypical depression in Parkinson's disease. Am J Psychiatry 1988, 145:1020-1022.
21. Marsh L: Anxiety disorders in Parkinson's disease. Int Rev Psychiatry 2000, 12:307-318.
22. Brown GL, Wilson WP: Parkinsonism and depression. South Med J 1972, 65:540-545.
23. Taylor AE, Saint-Cyr JA, Lang AE, Kenny FT: Parkinson's disease and depression: a critical re-evaluation. Brain 1986, 109:279-292.
24. Stenager EN, Wermuth L, Stenager E, Boldsen J: Suicide in patients with Parkinson's disease: an epidemiological study. Acta Psychiatr Scand 1994, 90:70-72.
25. Starkstein SE, Preziosi TJ, Forrester AW, Robinson RG: Specificity of affective and autonomic symptoms of depression in Parkinson's disease. J Neurol Neurosurg Psychiatry 1990, 53:869-873.
26. Cummings JL: Depression and Parkinson's disease: a review. Am J Psychiatry 1992, 149:443-454.
27. Mayeux R, Stern Y, Rosen J, Leventhal J: Depression, intellectual impairment, and Parkinson disease. Neurology 1981, 31:645-650.
28. Starkstein SE, Preziosi TJ, Bolduc PL, Robinson RG: Depression in Parkinson's disease. J Nerv Ment Dis 1990, 178:27-31.
29. Starkstein SE, Robinson RG: Dementia of depression in Parkinson's disease and stroke. J Nerv Ment Dis 1991, 179:593-601.
30. Kuzis G, Sabe L, Tiberti C, et al.: Cognitive functions in major depression and Parkinson disease. Arch Neurol 1997, 54:982-986.
31. Starkstein SE, Preziosi TJ, Berthier ML, et al.: Depression and cognitive impairment in Parkinson's disease. Brain 1989, 112:1141-1153.
32. Starkstein SE, Bolduc PL, Mayberg HS, et al.: Cognitive impairments and depression in Parkinson's disease: a follow-up study. J Neurol Neurosurg Psychiatry 1990, 53:597-602.
33. Norman S, Tröster AI, Fields JA, Brooks R: Effects of depression and Parkinson's disease on cognitive functioning. J Neuropsychiatry Clin Neurosci 2002, 14:31-36.
34. Tandberg E, Larsen JP, Aarsland D, Cummings JL: The occurrence of depression in Parkinson's disease: a community-based study. Arch Neurol 1996, 53:175-179.
35. Tandberg E, Larsen JP, Aarsland D, et al.: Risk factors for depression in Parkinson's disease. Arch Neurol 1997, 54:625-630.
36. Marder K, Tang MX, Cote L, et al.: The frequency and associated risk factors for dementia in patients with Parkinson's disease. Arch Neurol 1995, 52:695-701.
37. Tröster AI, Stalp LD, Paolo AM, et al.: Neuropsychological impairment in Parkinson's disease with and without depression. Arch Neurol 1995, 52:1164-1169.
38. Schrag A, Jahanshahi M, Quinn NP: What contributes to depression in Parkinson's disease? Psychol Med 2001, 31:65-73.
39. Gotham AM, Brown RG, Marsden CD: Depression in Parkinson's disease: a quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry 1986, 49:381-389.
40. Huber S, Paulson GW, Shuttleworth EC: Depression in Parkinson's disease. Neuropsychiat Neuropsychol Behav Neurol 1988, 1:47-51.
41. Sano M, Stern Y, Williams J, et al.: Coexisting dementia and depression in Parkinson's disease. Arch Neurol 1989, 46:1284-1286.
42. Fukunishi I, Hosokawa K, Ozaki S: Depression antedating the onset of Parkinson's disease. Jpn J Psychiatry Neurol 1991, 45:7-11.
43. Horn S: Some psychological factors in Parkinsonism. J Neurol Neurosurg Psychiatry 1974, 37:27-31.
44. Marsh GG, Markham CH: Does levodopa alter depression and psychopathology in Parkinsonism patients? J Neurol Neurosurg Psychiatry 1973, 36:925-935.
45. Robins AH: Depression in patients with Parkinsonism. Br J Psychiatry 1976, 128:141-145.
46. Rampello LCS, Raffaele R, Vecchio I, Nicoletti F: The SSRI, citalopram, improves bradykinesia in patients with Parkinson's disease treated with levodopa. Clin Neuropharmacol 2002, 25:21-24.
47. Wengel SP, Burke WJ, Pfeiffer RF, et al.: Maintenance electro-convulsive therapy for intractable Parkinson's disease. Am J Geriatr Psychiatry 1998, 6:263-269.
48. Mayeux R, Stern Y, Cote L, Williams JB: Altered serotonin metabolism in depressed patients with Parkinson's disease. Neurology 1984, 34:642-646.
49. Mayeux R, Stern Y, Sano M: The relationship of serotonin to depression in Parkinson's disease. Mov Disord 1988, 3:237-244.
50. Langer SZ, Galzin AM, Poirier MF: Association of the (3H)-imipramine and (3H)-paroxetine binding with the 5HT transporter in brain and platelets: relevance to studies in depression. J Receptor Res 1987, 7:499-521.
51. Raisman R, Cash R, Agid Y: Parkinson's disease: decreased density of (3H)-imipramine and (3H)-paroxetine binding sites in putamen. Neurology 1986, 36:556-560.
52. Mayberg HS, Starkstein SE, Sadzot B, et al.: Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease. Ann Neurol 1990, 28:57-64.
53. Ring HA, Bench CJ, Trimble MR, et al.: Depression in Parkinson's disease: a positron emission study. Br J Psychiatry 1994, 165:333-339.
54. Murai T, Müler U, Werheid K, et al.: In vivo evidence for differential association of striatal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2001, 13:222-228.
55. Mentis MJ, McIntosh AR, Perrine K, et al.: Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson's disease. Am J Psychiatry 2002, 159:746-754.
56. Klaassen T, Verhey FR, Sneijders GH, et al.: Treatment of depression in Parkinson's disease: a meta-analysis. J Neuropsychiatry Clin Neurosci 1995, 7:281-286.
57. Lemke MR: Effect of reboxetine on depression in Parkinson's disease patients. J Clin Psychiatry 2002, 63:300-304.
58. Zesiewicz TA, Hauser RA: Depression in Parkinson's disease. Curr Psychiatry Rep 2002, 4:69-73.
59. Oxman TE, Sengupta A: Treatment of minor depression. Am J Geriatr Psychiatry 2002, 10:256-264.
60. Richard IH, Maughn A, Kurlan R: Do serotonin reuptake inhibitor antidepressants worsen Parkinson's disease? A retrospective case series. Mov Disord 1999, 14:155-193.
61. Suchowersky O, de Vries JD: Interaction of fluoxetine and selegeline. Can J Psychiatry 1990, 35:571-572.
62. Olanow CW, Koller WC: An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. Neurology 1998, 50(suppl):S1-S57
63. Faber R, Trimble MR: Electroconvulsive therapy in Parkinson's disease and other movement disorders. Mov Disord 1991, 6:293-303.
64. Fetoni V, Soliveri P, Monza D, et al.: Affective symptoms in multiple system atrophy and Parkinson's disease: response to levodopa therapy. J Neurol Neurosurg Psychiatry 1999, 66:541-544.
65. Stein MB, Heuser IJ, Juncos JL, Uhde TW: Anxiety disorders in patients with Parkinson's disease. Am J Psychiatry 1990, 147:217-220.
66. Rubin AJ, Kurlan R, Miller C, Shoulson I: Atypical depression and Parkinson's disease [abstract]. Ann Neurol 1986, 20:150-150.
67. Vazquez A, Jimenez-Jimenez FJ, Garcia-Ruiz P, Garcia-Urra D: "Panic attacks" in Parkinson's disease: a long-term complication of levodopa therapy. Acta Neurol.Scand 1993, 87:14-18.
68. Menza MA, Robertson-Hoffman DE, Bonapace AS: Parkinson's disease and anxiety: comorbidity with depression. Biol Psychiatry 1993, 34:465-470.
69. Berrios GE, Campbell C, Politynska BE: Autonomic failure, depression and anxiety in Parkinson's disease. Br J Psychiatry 1995, 166:789-792.
70. Maricle RA, Nutt JG, Carter JH: Mood and anxiety fluctuation in Parkinson's disease associated with levodopa infusion: preliminary findings. Mov Disord 1995, 10:329-332.
71. Richard IH, Justus AW, Kurlan R: Relationship between mood and motor fluctuations in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2001, 13:35-41.
72. Richard IH, Szegethy E, Lichter D, et al.: Parkinson's disease: a preliminary study of yohimbine challenge in patients with anxiety. Clin Neuropharmacol 1999, 22:172-175.
73. Iruela LM, Ibanez-Rojo V, Palanca I, Caballero L: Anxiety disorders and Parkinson's disease. Am J Psychiatry 1992, 149:719-720.
74. Cash R, Dennis T, L'Heureux R, et al.: Parkinson's disease and dementia: norepinephrine and dopamine in locus ceruleus. Neurology 1987, 37:42-46.
75. Lauterbach EC: The locus ceruleus and anxiety disorders in demented and nondemented familial Parkinsonism. Am J Psychiatry 1993, 150:994
76. Higginson CI, Fields JA, Tröster AI: Which symptoms of anxiety diminish after surgical interventions for Parkinson's disease? Neuropsychiat Neuropsychol Behav Neurol 2001, 14:117-121.
77. Higginson CI, Fields JA, Koller WC, Tröster AI: Questionnaire assessment potentially overestimates anxiety in Parkinson's disease. J Clin Psychol 2001, 8:95-99.
78. Marsh L, Solvasson B, Cahn DA, et al.: Psychiatric outcome after pallidotomy for Parkinson's disease. Biol Psychiatry 1997, 41:107S.
79. Scott R, Gregory R, Hines N, et al.: Neuropsychological, neurological and functional outcome following pallidotomy for Parkinson's disease. Brain 1998, 121:659-675.
80. Marin RS: Differential diagnosis of apathy and related disorders of diminished motivation. Psychiatr Ann 1997, 27:30-33.
81. Starkstein SE, Mayberg HS, Preziosi TJ, et al.: Reliability, validity, and clinical correlates of apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1992, 4:134-139.
82. Isella V, Melzi P, Grimaldi M, et al.: Clinical, neuropsychological, and morphometric correlates of apathy in Parkinson's disease. Mov Disord 2002, 17:366-371.
83. Levy ML, Cummings JL, Fairbanks LA, et al.: Apathy is not depression. J Neuropsychiatry Clin Neurosci 1998, 10:314-319.
84. Marin RS: Differential diagnosis and classification of apathy. Am J Psychiatry 1990, 147:22-30.
85. Richard IH, Kurlan R, Parkinson Study Group: A survey of antidepressant usage in Parkinson's disease. Neurology 1997, 49:1168-1170.
86. Gelenberg AJ: Apathy and new antidepressants. Biol Ther Psychiatry Newsletter 1991, 14:925-925.
87. Duffy JD: The neural substrates of motivation. Psychiatr Ann 1997, 27:39-43.
88. Mayeux R, Stern Y, Sano M: Clinical and biochemical correlates of bradyphrenia in Parkinson's disease. Neurology 1987, 37:1130-1134.
89. Marin RS, Fogel BS, Duffy J, Krupp B: Apathy: a treatable syndrome. J Neuropsychiatry Clin Neurosci 1995, 7:23-30.
90. Cummings JL: Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry 2000, 157:4-15.
91. Shulman LM: Apathy in patients with Parkinson's disease. Int Rev Psychiatry 2000, 12:298-306.
92. Goetz CG, Pappert EJ, Blasucci LM: Intravenous levodopa in chronically treated hallucinating Parkinson's patients: high-dose pharmacological challenge does not precipitate visual hallucinations. Neurology 1998, 50:515-517.
93. Holroyd S, Currie L, Wooten GF: Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry 2001, 70:734-738.
94. Aarsland D, Larsen JP, Cummings JL, Laake K: Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 1999, 56:595-601.
95. Cannas A, Spissu A, Floris GL, et al.: Chronic delusional hallucinatory psychosis in early-onset Parkinson's disease: drug-induced complication or sign of an idiopathic psychiatric illness? Neurol Sci 2001, 22:53-54.
96. Goetz CG, Vogel C, Tanner CM, Stebbins GT: Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology 1998, 51:811-814.
97. Goetz CG, Leurgans S, Pappert EJ, et al.: Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology 2001, 57:2078-2082.
98. Peyser CE, Naimark D, Zuniga R, Jeste DV: Psychoses in Parkinson's disease. Semin Clin Neuropsychiatry 1998, 3:41-50.
99. Goetz CG, Burke PF, Leurgans S, et al.: Genetic variation analysis in Parkinson disease patients with and without hallucinations. Arch Neurol 2001, 58:209-213.
100. Makoff AJ, Greaham JM, Arranz MJ, Forsyth J: Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease. Pharmacogenetics 2000, 10:43-48.
101. Hutchinson M, Fazzini E: Cholinesterase inhibition in Parkinson's disease [letter]. J Neurol Neurosurg Psychiatry 1996, 61:324-325.
102. Birkmayer W, Riederer P: Responsibility of extrastriatal areas for the appearance of psychotic symptoms. J Neural Transm 1975, 37:175-182.
103. Juncos JL: Management of psychotic aspects of Parkinson's disease. J Clin Psychiatry 1999, 60:42-53.
104. Goetz CG, Blasucci LM, Leurgans S, Pappert EJ: Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 2000, 55:789-794.
105. Parkinson Study Group: Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999, 340:757-763.
106. Ellis T, Cudkowicz ME, Sexton PM, Growdon JH: Clozapine and risperidone treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2000, 12:364-369.
107. Factor SA, Friedman JH, Lannon MC, et al.: Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial. Mov Disord 2001, 16:135-139.
108. Fernandez HH, Lannon MC, Friedman JH, et al.: Clozapine replacement by quetiapine for the treatment of drug induced psychosis in Parkinson's disease. Mov Disord 2000, 15:579-581.
109. Reddy S, Factor SA, Molho ES, Feustel PJ: The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord 2002, 17:676-681.
110. Fernandez HH, Trieschman ME, Burke MA, Friedman JH: Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies. J Clin Psychiatry 2002, 63:513-515.
111. Wolters EC: Dopaminomimetic psychosis in Parkinson's disease patients. Neurology 1999, 52(suppl):S10-S13.
112. Giménez-Roldán S, Mateo D, Navarro E, Ginés MM: Efficacy and safety of clozapine and olanzapine: an open-label study comparing two groups of Parkinson's disease patients with dopaminergic-induced psychosis. Parkinsonism Related Disord 2001, 7:121-127.
113. Marsh L, Lyketsos C, Reich SG: Olanzapine for the treatment of psychosis in patients with Parkinson's disease and dementia. Psychosomatics 2001, 42:477-481.
114. Factor SA, Molho ES, Podskalny GD, Brown D: Parkinson's disease: drug-induced psychiatric states. Adv Neurol 1995, 65:115-138.
115. Reading PJ, Luce AK, McKeith IG: Rivastigmine in the treatment of Parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 2001, 16:1171-1195.
116. Obeso JA, Guridi J, DeLong MR: Surgery for Parkinson's disease. J Neurol Neurosurg Psychiatry 1997, 62:2-8.
117. Hely MA, Fung VSC, Morris JGL: Treatment of Parkinson's disease. J Clin Neurosci 2000, 7:484-494.
118. Dowsey-Limousin P, Pollak P: Deep brain stimulation in the treatment of Parkinson's disease: a review and update. Clin Neurosci Res 2001, 1:521-526.
119. Brundin P, Hagell P: The neurobiology of cell transplantation in Parkinson's disease. Clin Neurosci Res 2001, 1:507-520.
120. Marsden CD, Obeso JA: The functions of the basal ganglia and the paradox of stereotaxic surgery in Parkinson's disease. Brain 1994, 117:877-897.
121. Alexander GE, DeLong MR, Strick PL: Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986, 9:357-381.
122. Parent A, Cicchetti F: The current model of basal ganglia organization under scrutiny. Mov Disord 1998, 13:199-202.
123. Brooks DJ, Samuel M: The effects of surgical treatment on Parkinson's disease on brain function: PET findings. Neurology 2000, 55(suppl):S52-S59.
124. Saint-Cyr JA, Trépanier LL: Neuropsychologic assessment of patients for movement disorder surgery. Mov Disord 2000, 15:771-783.
125. Trépanier LL, Kumar R, Lozano AM, et al.: Neuropsychological outcome of GPi pallidotomy and GPi or STN deep brain stimulation in Parkinson's disease. Brain Cogn 2000, 42:324-347.
126. Lopiano L, Rizzone M, Bergamasco B, et al.: Deep brain stimulation of the subthalamic nucleus in PD: an analysis of the exclusion cases. J Neurol Sci 2002, 195:167-170.
127. Tröster AI, Fields JA, Wilkinson SB, et al.: Neuropsychological functioning before and after unilateral thalamic stimulating electrode implantation in Parkinson's disease. Neurosurg Focus 1997, 2:1-6.
128. Woods SP, Fields JA, Lyons KE, et al.: Neuropsychological and quality of life changes following unilateral thalamic deep brain stimulation in Parkinson's disease: a 1-year follow-up. Acta Neurochir (Wien) 2001, 143:1273-1278.
129. Perozzo P, Rizzone M, Bergamasco B, et al.: Deep brain stimulation of the subthalamic nucleus in Parkinson's disease: comparison of pre-and postoperative neuropsychological evaluation. J Neurol Sci 2001, 192:9-15.
130. Scott RB, Harrison J, Boulton C, et al.: Global attentional-executive sequelae following surgical lesions to globus pallidus interna. Brain 2002, 125:562-574.
131. Martínez-Martín P, Valldeoriola F, Tolosa E, et al.: Bilateral subthalamic nucleus stimulation and quality of life in advanced Parkinson's disease. Mov Disord 2002, 17:372-377.
132. Romito LMA, Scerrati M, Contarino MF, et al.: Long-term follow up of subthalamic stimulation in Parkinson's disease. Neurology 2002, 58:1546-1550.
133. Bejjani B, Damier P, Arnulf I, et al.: Transient acute depression induced by high-frequency deep-brain stimulation. N Engl J Med 1999, 340:1476-1480.
134. Miyawaki E, Perlmutter JS, Tröster AI, et al.: The behavioral complications of pallidal stimulation: a case report. Brain Cogn 2000, 42:417-434.
135. Merello M, Starkstein S, Nouzeilles MI, et al.: Bilateral pallidotomy for treatment of Parkinson's disease induced corticobulbar syndrome and psychic akinesia avoidable by globus pallidus lesion combined with contralateral stimulation. J Neurol Neurosurg Psychiatry 2001, 71:611-614.
136. Riordan HJ, Flashman LA, Roberts DW: Neurocognitive and psychosocial correlates of ventroposterolateral pallidotomy surgery in Parkinson's disease. Neurosurg Focus 1997, 2:1-9.
137. Masterman D, DeSalles A, Baloh RW, et al.: Motor, cognitive, and behavioral performance following unilateral ventroposterior pallidotomy for Parkinson disease. Arch Neurol 1998, 55:1201-1208.
138. Baron MS, Vitek JL, Bakay RAE, et al.: Treatment of advanced Parkinson's disease by unilateral posterior GPi pallidotomy: 4-year results of a pilot study. Mov Disord 2000, 15:230-237.